The anti-angiogenic potential of (±) gossypol in comparison to suramin
- 198 Downloads
Cotton, a staple fiber that grows around the seeds of the cotton plants (Gossypium), is produced throughout the world, and its by products, such as cotton fibers, cotton-seed oil, and cottonseed proteins, have a variety of applications. Cotton-seed contains gossypol, a natural phenol compound. (±)-Gossypol is a yellowish polyphenol that is derived from different parts of the cotton plant and contains potent anticancer properties. Tumor growth and metastasis are mainly related to angiogenesis; therefore, anti-angiogenic therapy targets the new blood vessels that provide oxygen and nutrients to actively proliferating tumor cells. The aim of the present study was to evaluate the anti-angiogenic potential of (±)-gossypol in vitro. (±)-Gossypol has anti-proliferative effects on cancer cell lines; however, its anti-angiogenic effects on normal cells have not been studied. Anti-proliferative activities of gossypol assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, anti-angiogenic activities using tube formation assay, and cell migration inhibition capability using a wound-healing assay on human umbilical vein endothelial cells (HUVECs) were revealed. (±)-Gossypol displayed the following potent anti-angiogenic activities in vitro: it inhibited the cell viability of HUVECs, it inhibited the migration of HUVECs, and disrupted endothelial tube formation in a dose-dependent manner. In addition, the anti-angiogenic effects of (±)-gossypol were investigated in ovo in a model using a chick chorioallantoic membrane (CAM). Decreases in capillary density were assessed and scored. (±)-Gossypol showed dose-dependent anti-angiogenic effects on CAM. These findings suggest that (±)-gossypol can be used as a new anti-angiogenic agent.
KeywordsAnti-angiogenesis (±)-Gossypol Human umbilical vein endothelial cell (HUVEC) Suramin
This study was supported by the Scientific Research Council of Ege University (Project No: 2011-FEN-006).
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest associated with this study or its results.
- Benvenuto M, Mattera R, Masuelli L, Taffera G, Andracchio O, Tresoldi I, Lido P, Giganti MG, Godos J, Modesti A, Bei R (2017) (±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. Int J Food Sci Nutr 68:298–312CrossRefGoogle Scholar
- Chang CJG, Ghosh PK, Hu YF, Brueggmeier RW, Lin YC (1993) Antiproliferative and antimetastatic effect of gossypol on Dunning prostatic cell-bearing Copenhagen rats. Res Commun Chem Pathol Pharmacol 76:293–312Google Scholar
- Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT (2014) Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer 111:2275–2286CrossRefGoogle Scholar
- Shen S, Wu Y, Li K, Wang Y, Wu J, Zeng Y, Wu D (2018) Versatile hyaluronic acid modified AQ4N-Cu (II)-gossypol infinite coordination polymer nanoparticles: multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring. Biomaterials 154:197–212CrossRefGoogle Scholar
- Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C (2001) Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66:239–248CrossRefGoogle Scholar